About this Research Topic
This Research Topic is the second volume of “Cardiogenic shock: Basic and clinical consideration”. Please see the first volume here.
Cardiogenic shock remains a major problem in cardiovascular medicine with high mortality despite available treatments. There are a limited number of proven therapies despite many clinical trials, and substantial gaps in knowledge remain. Cardiogenic shock is also a heterogeneous illness, and treatment needs to be individualized, creating challenges in designing randomized clinical trials. Advances in understanding of molecular biology and pathophysiology of cardiogenic shock, refined tools for risk stratification, defining timing, modality, and duration of mechanical circulatory support, development of new medical therapies, establishment of cardiogenic shock systems of care, and recognition of irreversible shock are all important to improve shock management and outcomes.
The objectives of this research topic are to evaluate basic, translational, and clinical aspects of cardiogenic shock. Specifically, the Topic Editors would encourage submissions on the following topics:
1) Biologic pathways in early and late cardiogenic shock, and potential targets for therapeutic interventions.
2) Biomarkers in cardiogenic shock and their diagnostic/prognostic implications.
3) Clinical tools for risk stratification.
4) The role of mechanical circulatory support: in whom, what device, when, how?
5) The role of medical therapies in management of cardiogenic shock.
Original research articles, reviews, and commentaries are encouraged with sub-themes including, but not limited to:
1) Animal models of cardiogenic shock.
2) Biological pathways in cardiogenic shock in animal models and humans: similarities and differences.
3) Varying etiologies of shock: how are they different? (eg. MI, non-MI, peripartum, chronic HF etc).
4) Cardiac arrest and cardiogenic shock: clinical considerations.
5) Influence of different types of MCS on biochemical pathways, hemodynamics, infarction size, biomarkers.
6) Which MCS device for which patient? How do you choose among them?
7) LV decompression during peripheral VA ECMO: techniques, hemodynamics, outcomes.
8) Bridging strategies in cardiogenic shock: recovery, LVAD, transplant.
9) Population differences in cardiogenic shock: age, gender, ethnicity.
10) Cost-effectiveness analyses.
11) Shock systems of care: how to develop.
12) Newer therapies: novel inotropic agents, heart rate modification, targeted temperature management.
13) What is too sick/irreversible shock and time for palliative therapy?
Cardiogenic shock remains a major problem in cardiovascular medicine with high mortality despite available treatments. There are a limited number of proven therapies despite many clinical trials, and substantial gaps in knowledge remain. Cardiogenic shock is also a heterogeneous illness, and treatment needs to be individualized, creating challenges in designing randomized clinical trials. Advances in understanding of molecular biology and pathophysiology of cardiogenic shock, refined tools for risk stratification, defining timing, modality, and duration of mechanical circulatory support, development of new medical therapies, establishment of cardiogenic shock systems of care, and recognition of irreversible shock are all important to improve shock management and outcomes.
The objectives of this research topic are to evaluate basic, translational, and clinical aspects of cardiogenic shock. Specifically, the Topic Editors would encourage submissions on the following topics:
1) Biologic pathways in early and late cardiogenic shock, and potential targets for therapeutic interventions.
2) Biomarkers in cardiogenic shock and their diagnostic/prognostic implications.
3) Clinical tools for risk stratification.
4) The role of mechanical circulatory support: in whom, what device, when, how?
5) The role of medical therapies in management of cardiogenic shock.
Original research articles, reviews, and commentaries are encouraged with sub-themes including, but not limited to:
1) Animal models of cardiogenic shock.
2) Biological pathways in cardiogenic shock in animal models and humans: similarities and differences.
3) Varying etiologies of shock: how are they different? (eg. MI, non-MI, peripartum, chronic HF etc).
4) Cardiac arrest and cardiogenic shock: clinical considerations.
5) Influence of different types of MCS on biochemical pathways, hemodynamics, infarction size, biomarkers.
6) Which MCS device for which patient? How do you choose among them?
7) LV decompression during peripheral VA ECMO: techniques, hemodynamics, outcomes.
8) Bridging strategies in cardiogenic shock: recovery, LVAD, transplant.
9) Population differences in cardiogenic shock: age, gender, ethnicity.
10) Cost-effectiveness analyses.
11) Shock systems of care: how to develop.
12) Newer therapies: novel inotropic agents, heart rate modification, targeted temperature management.
13) What is too sick/irreversible shock and time for palliative therapy?
Keywords: cardiogenic shock
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
